Claims

1. Use of niraparib or a salt thereof in the manufacture of a medicament for the treatment of prostate cancer wherein the medicament is to be administered in a safe and effective amount to a human in need thereof and wherein the prostate cancer is antiandrogen resistant.

2. The use of claim 1, wherein the prostate cancer is a castration-resistant prostate cancer or metastatic castration-resistant prostate cancer.

3. The use of claim 1 or claim 2, wherein the prostate cancer is carrying at least one DNA repair anomaly selected from the group consisting of BRCA-1, BRCA-2, FANCA, PALB2, CHEK2, BRIP1, HDAC2, and ATM.

4. The use of claim 3, wherein the DNA repair anomaly is BRCA-1 or BRCA-2.

5. The use of claim 4, wherein the prostate cancer is castration-resistant prostate cancer.

6. The use of claim 4, wherein the prostate cancer is metastatic castration-resistant prostate cancer.

7. The use of claim 5, wherein niraparib is to be administered in an amount of from 30 mg/day to 400 mg/day.

8. The use of claim 7, wherein the amount of niraparib to be administered is 300 mg/day.

9. The use of claim 8, wherein niraparib is to be administered as once daily oral administration in three 100 mg oral dosage forms.

10. Use of niraparib or a salt thereof in the manufacture of a medicament for the treatment of castration and antiandrogen resistant prostate cancer in a human wherein the medicament is to be administered in three 100 mg oral dosage forms once daily.

11. The use of claim 6, wherein the prostate cancer is carrying at least one DNA repair anomaly selected from the group consisting of BRCA-1, BRCA-2, FANCA, PALB2, CHEK2, BRIP1, HDAC2, and ATM.

12. The use of claim 11, wherein the DNA repair anomaly is BRCA-1 or BRCA-2.

13. The use of claim 1 or claim 6, wherein the prostate cancer is carrying at least one bi-allelic DNA repair anomaly selected from the group consisting of BRCA-1, BRCA-2, FANCA, PALB2, CHEK2, BRIP1, HDAC2, and ATM.

14. The use of claim 13, wherein the DNA repair anomaly is BRCA-1 or BRCA-2.

15. The use of claim 1 or claim 2, wherein the prostate cancer is not BRCA deficient.

16. The use of claim 1 or claim 2, wherein the prostate cancer carries at least one DNA repair anomaly selected from the group consisting of FANCA, PALB2, CHEK2, BRIP1, HDAC2, and ATM.

17. The use of claim 1 or claim 2, wherein the prostate cancer has been exposed to at least one line of taxane-based chemotherapy.

18. The use of claim 1 or claim 2, wherein the prostate cancer has been exposed to at least one line of enzalutamide-, apalutamide-, or abiraterone acetate-based chemotherapy.